Beverly A Teicher

Beverly A Teicher

UNVERIFIED PROFILE

Are you Beverly A Teicher?   Register this Author

Register author
Beverly A Teicher

Beverly A Teicher

Publications by authors named "Beverly A Teicher"

Are you Beverly A Teicher?   Register this Author

100Publications

2281Reads

30Profile Views

Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines.

Cancer Chemother Pharmacol 2019 Oct 31;84(4):771-780. Epub 2019 Jul 31.

Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 9609 Medical Center Dr., Rockville, MD, 20850, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03898-zDOI Listing
October 2019

Exposure time versus cytotoxicity for anticancer agents.

Cancer Chemother Pharmacol 2019 Aug 17;84(2):359-371. Epub 2019 May 17.

Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03863-wDOI Listing
August 2019

Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?

Lung Cancer Manag 2019 Aug 21;8(2):LMT13. Epub 2019 Aug 21.

National Cancer Institute, Division of Cancer Treatment & Diagnosis, Rockville, MD 20850, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/lmt-2019-0005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802707PMC
August 2019

A Vision from the New Editor-in-Chief.

Mol Cancer Ther 2019 03;18(3):497

National Cancer Institute/National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-19-0094DOI Listing
March 2019

CD248: A therapeutic target in cancer and fibrotic diseases.

Oncotarget 2019 Jan 29;10(9):993-1009. Epub 2019 Jan 29.

Molecular Pharmacology Branch, Developmental Therapeutics Program, DCTD, National Cancer Institute, Bethesda 20892, MD, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/26590
Publisher Site
http://dx.doi.org/10.18632/oncotarget.26590DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398180PMC
January 2019

Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.

Cancer Med 2017 Aug 1;6(8):1952-1964. Epub 2017 Aug 1.

Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, 21702.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1131DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548882PMC
August 2017

3D Models of the NCI60 Cell Lines for Screening Oncology Compounds.

SLAS Discov 2017 06 13;22(5):473-483. Epub 2017 Mar 13.

1 Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Lab for Cancer Research, Frederick, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2472555217697434DOI Listing
June 2017

Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.

J Natl Cancer Inst 2016 10 31;108(10). Epub 2016 May 31.

Affiliations of authors: Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD (DE, TS, RD, JL, CO, RR, MS, JC, EH, NF, AM); Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis (MK, GK, JM, BAT), Biometric Research Program, Division of Cancer Treatment and Diagnosis (EP, DS), and Cancer Therapy Evaluation Program (SM), National Cancer Institute, Rockville, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279282PMC
October 2016

Antibody-drug conjugates for cancer therapy.

Lancet Oncol 2016 06;17(6):e254-e262

Thoracic and GI Oncology Branch, National Cancer Institute, Bethesda, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045163003
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(16)30030-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601617PMC
June 2016

Bioenergetic properties of human sarcoma cells help define sensitivity to metabolic inhibitors.

Cell Cycle 2014 10;13(7):1152-61. Epub 2014 Feb 10.

Molecular Pharmacology Branch; Leidos Biomedical Research, Inc.; Frederick National Laboratory for Cancer Research; Frederick, MD USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.28010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013165PMC
May 2016

What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?

Am Soc Clin Oncol Educ Book 2015 :e117-25

From the Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; National Cancer Institute at the National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e117DOI Listing
February 2016

Bromodomain and hedgehog pathway targets in small cell lung cancer.

Cancer Lett 2016 Feb 10;371(2):225-39. Epub 2015 Dec 10.

Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2015.12.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738144PMC
February 2016

Proteasome inhibitors.

Biochem Pharmacol 2015 Jul 29;96(1):1-9. Epub 2015 Apr 29.

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2015.04.008DOI Listing
July 2015

CCR 20th anniversary commentary: In the beginning, there was PS-341.

Clin Cancer Res 2015 Mar;21(5):939-41

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2549DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349205PMC
March 2015

Combining targeted agents with modern radiotherapy in soft tissue sarcomas.

J Natl Cancer Inst 2014 Nov 18;106(11). Epub 2014 Oct 18.

Department of Radiation Oncology, Centre Hospitalier de L'Université de Montréal, Montréal, Québec, Canada (PW); Research Institute at Nationwide Children's Hospital, Columbus, OH (PH); Departments of Radiation Oncology and Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC (DGK); 21st Century Oncology Translational Research Consortium (TRC) Headquarters, Scottsdale, AZ (SEF); Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA (AMM); Department of Radiation Oncology, the Ohio State University, Columbus, OH (MXW); Department of Radiation Oncology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA (APD); Radiotherapy Development Branch & Molecular Radiation Therapeutics Branch, Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (MA, CNC); Clinical Radiation Oncology Branch, National Cancer Institute, Bethesda, MD (BV); Molecular Pharmacology Branch, National Cancer Institute, Bethesda, MD (BAT); Department of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH (MM); Winship Cancer Institute, Woodruff Health Science Center, Emory University, Atlanta, GA (WJC); Department of Radiation Oncology, Rush University Medical Center, Chicago, IL (DW).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju329DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207861PMC
November 2014

Antibody drug conjugates.

Curr Opin Oncol 2014 Sep;26(5):476-83

National Cancer Institute, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000108DOI Listing
September 2014

Targets in small cell lung cancer.

Biochem Pharmacol 2014 Jan 30;87(2):211-9. Epub 2013 Sep 30.

National Cancer Institute, Bethesda, MD, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2013.09.014DOI Listing
January 2014

Perspective: Opportunities in recalcitrant, rare and neglected tumors.

Oncol Rep 2013 Sep 2;30(3):1030-4. Epub 2013 Jul 2.

Molecular Pharmacology Branch, Developmental Therapeutics Program, National Cancer Institute, Rockville, MD 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2013.2581DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3783063PMC
September 2013

Analyses of the combination of 6-MP and dasatinib in cell culture.

Int J Oncol 2013 Jul 2;43(1):13-22. Epub 2013 May 2.

Molecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2013.1930DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742163PMC
July 2013

The promise of antibody-drug conjugates.

N Engl J Med 2012 Nov;367(19):1847-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1211736DOI Listing
November 2012

Targeting cancer metabolism.

Clin Cancer Res 2012 Oct;18(20):5537-45

Molecular Pharmacology Branch, Developmental Therapeutics Program, National Cancer Institute, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-2587DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475613PMC
October 2012

Searching for molecular targets in sarcoma.

Biochem Pharmacol 2012 Jul 22;84(1):1-10. Epub 2012 Feb 22.

Molecular Pharmacology Branch, Developmental Therapeutics Program, National Cancer Institute, 6130 Executive Boulevard, Rockville, MD 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2012.02.009DOI Listing
July 2012

Human choriocarcinomas: placental growth factor-dependent preclinical tumor models.

Int J Oncol 2012 Feb 10;40(2):479-86. Epub 2011 Nov 10.

Genzyme Corporation, 49 New York Ave., Framingham, MA 01701-9322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2011.1257DOI Listing
February 2012

Endosialin expression in side populations in human sarcoma cell lines.

Oncol Lett 2012 Feb 14;3(2):325-329. Epub 2011 Nov 14.

Genzyme Corporation, Framingham, MA 01701, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2011.478DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362650PMC
February 2012

Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells.

Cancer Chemother Pharmacol 2011 Dec 28;68(6):1537-46. Epub 2011 Apr 28.

Genzyme Corporation, 49 New York Ave, Framingham, MA 01701-9322, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-011-1658-0
Publisher Site
http://dx.doi.org/10.1007/s00280-011-1658-0DOI Listing
December 2011

Tumor endothelial marker 7 (TEM-7): a novel target for antiangiogenic therapy.

Microvasc Res 2011 Nov 17;82(3):253-62. Epub 2011 Sep 17.

Genzyme Corporation, 49 New York Ave., Framingham, MA 01701, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mvr.2011.09.004DOI Listing
November 2011

Antibody conjugate therapeutics: challenges and potential.

Clin Cancer Res 2011 Oct;17(20):6389-97

Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-11-1417DOI Listing
October 2011

Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.

Mol Cancer Ther 2011 Aug 2;10(8):1490-9. Epub 2011 Jun 2.

Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-10-1043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155218PMC
August 2011

Characteristics of human Ewing/PNET sarcoma models.

Ann Saudi Med 2011 Mar-Apr;31(2):174-82

Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0256-4947.78206DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102479PMC
July 2011

Placental growth factor upregulation is a host response to antiangiogenic therapy.

Clin Cancer Res 2011 Mar 22;17(5):976-88. Epub 2011 Feb 22.

Genzyme Corporation, Framingham, Massachusetts 01701, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-2687DOI Listing
March 2011

Antiangiogenic agents and targets: A perspective.

Biochem Pharmacol 2011 Jan 12;81(1):6-12. Epub 2010 Oct 12.

Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701-9322, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00062952100072
Publisher Site
http://dx.doi.org/10.1016/j.bcp.2010.09.023DOI Listing
January 2011

Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs.

Curr Opin Pharmacol 2010 Aug 22;10(4):397-404. Epub 2010 May 22.

Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701-9322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coph.2010.04.014DOI Listing
August 2010

CXCL12 (SDF-1)/CXCR4 pathway in cancer.

Clin Cancer Res 2010 Jun 18;16(11):2927-31. Epub 2010 May 18.

Genzyme Corporation, Framingham, Massachusetts 01701-9322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-2329DOI Listing
June 2010

Human tumor xenografts and mouse models of human tumors: re-discovering the models.

Expert Opin Drug Discov 2009 Dec 7;4(12):1295-305. Epub 2009 Nov 7.

Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701-9322, USA +1 508 271 2843 ; +1 508 620 1203 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17460440903380430DOI Listing
December 2009

Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.

Cancer Chemother Pharmacol 2009 Oct 10;64(5):1029-38. Epub 2009 Mar 10.

Genzyme Corporation, Framingham, MA 01701, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-009-0959-zDOI Listing
October 2009

Acute and chronic in vivo therapeutic resistance.

Biochem Pharmacol 2009 Jun 22;77(11):1665-73. Epub 2009 Jan 22.

Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701-9322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2009.01.006DOI Listing
June 2009

Flipping the wound that doesn't heal: the upside of coagulation in cancer.

Blood 2009 May;113(20):4827-8

Genzyme Corporation, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2009-03-207316DOI Listing
May 2009

Netrin-4 regulates angiogenic responses and tumor cell growth.

Exp Cell Res 2009 Mar 6;315(5):784-94. Epub 2008 Dec 6.

Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2008.11.018DOI Listing
March 2009

In vivo/ex vivo and in situ assays used in cancer research: a brief review.

Toxicol Pathol 2009 Jan 19;37(1):114-22. Epub 2008 Dec 19.

Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701-9322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0192623308329473DOI Listing
January 2009

Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization.

Microvasc Res 2008 Nov 8;76(3):180-8. Epub 2008 Aug 8.

Genzyme Corporation, 49 New York Avenue Framingham, MA 01701-9322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mvr.2008.07.008DOI Listing
November 2008

Treatment of transforming growth factor-beta-insensitive mouse Renca tumor by transforming growth factor-beta elimination.

Urology 2008 Jul 4;72(1):225-9. Epub 2008 Mar 4.

Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2007.11.091DOI Listing
July 2008

Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.

Biochem Pharmacol 2008 Mar 22;75(6):1262-71. Epub 2007 Oct 22.

Genzyme Corporation, 1 Mountain Road, Framingham, MA 01701-9322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2007.10.016DOI Listing
March 2008

Newer cytotoxic agents: attacking cancer broadly.

Clin Cancer Res 2008 Mar;14(6):1610-7

Genzyme Corporation, Framingham, Massachusetts 01701-9322, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-07-2249DOI Listing
March 2008

Transforming growth factor-beta and the immune response to malignant disease.

Clin Cancer Res 2007 Nov;13(21):6247-51

Genzyme Corporation, Framingham, Massachusetts 01701-9322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1654DOI Listing
November 2007

Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta.

J Immunol 2007 Mar;178(5):2883-92

Department of Urology, Northwestern University Medical School, 303 East Chicago Avenue, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.178.5.2883DOI Listing
March 2007

Newer vascular targets: endosialin (review).

Int J Oncol 2007 Feb;30(2):305-12

Genzyme Corporation, Framingham, MA 01701-9322, USA.

View Article

Download full-text PDF

Source
February 2007

Tumor models for efficacy determination.

Mol Cancer Ther 2006 Oct;5(10):2435-43

Genzyme Corporation, 1 Mountain Road, Framingham, MA 01701, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-06-0391DOI Listing
October 2006

Protein kinase C as a therapeutic target.

Clin Cancer Res 2006 Sep;12(18):5336-45

Genzyme Corporation, Framingham, Massachusetts 01701-9322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0945DOI Listing
September 2006

TGF-beta in cancer and as a therapeutic target.

Biochem Pharmacol 2006 Aug 10;72(5):523-9. Epub 2006 Mar 10.

Genzyme Corporation, 1 Mountain Road, Framingham, MA 01721, United States.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S000629520600157
Publisher Site
http://dx.doi.org/10.1016/j.bcp.2006.03.004DOI Listing
August 2006

Tumor models for preclinical development of targeted agents.

Prog Drug Res 2005 ;63:43-66

Genzyme Corporation, 1 Mountain Road, Framingham, MA 01701, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/3-7643-7414-4_3DOI Listing
November 2005

Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy.

Cancer Res 2005 Nov;65(21):9741-50

Genzyme Corp., Framingham, Massachusetts 01701-9322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-4337DOI Listing
November 2005

Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions.

J Clin Oncol 2005 Feb;23(6):1295-311

Division of Medical Oncology, S. Filippo Neri Hospital, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.10.022DOI Listing
February 2005

Alterations in vascular gene expression in invasive breast carcinoma.

Cancer Res 2004 Nov;64(21):7857-66

Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-1976DOI Listing
November 2004

Murine endothelial cell lines as models of tumor endothelial cells.

Clin Cancer Res 2004 Mar;10(6):2179-89

Genzyme Corporation, Framingham, Massachusetts 01701, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.ccr-03-1013DOI Listing
March 2004

LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice.

Cancer Chemother Pharmacol 2004 Feb 31;53(2):133-40. Epub 2003 Oct 31.

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-003-0713-xDOI Listing
February 2004

Identification of genes expressed in malignant cells that promote invasion.

Cancer Res 2003 Dec;63(24):8939-47

Genzyme Corporation, Framingham, Massachusetts 01701-9322, USA.

View Article

Download full-text PDF

Source
December 2003

Myofibroblasts enable invasion of endothelial cells into three-dimensional tumor cell clusters: a novel in vitro tumor model.

Cancer Chemother Pharmacol 2003 Oct 17;52(4):263-9. Epub 2003 Jul 17.

Department of Tumor Biology, Genzyme Molecular Oncology, Genzyme Corporation, Five Mountain Road, Framingham, MA 01701, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-003-0664-2DOI Listing
October 2003

Assays for in vitro and in vivo synergy.

Methods Mol Med 2003 ;85:297-321

Genzyme Corporation, Framingham, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1385/1-59259-380-1:297DOI Listing
June 2003

Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology.

Cancer Chemother Pharmacol 2003 Apr 18;51(4):321-7. Epub 2003 Mar 18.

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-003-0572-5DOI Listing
April 2003

An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy.

Cancer Res 2002 Oct;62(19):5597-602

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.

View Article

Download full-text PDF

Source
October 2002

Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.

Invest New Drugs 2002 Aug;20(3):241-51

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1016297611825DOI Listing
August 2002